fda icn icn resume test aid drug food drug administration allow icn pharmaceutical resume test ribavirin experimental aid drug accord icn safety concern sufficient magnitude withhold approval clinical study design ass safety efficacy ribavirin fda icn chairman milan panic october letter public icn fda spokesman confirm authenticity letter icn test drug human block spring fda decide insufficient evidence effectiveness common aidsrelated condition test intend determine ribavirin effective aidsrelated complex arc lymphadenopathy syndrome fda commissioner frank disclose agency investigate suspicious result submit icn antiviral drug personally scold icn official exaggerate claim drug addition house subcommittee probe icn trade financial irregularity fda let icn ribavirin safety effectiveness patient arc 
